TrialPloS one2011

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

Craig R Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.